Proton Beam Therapy for Treatment of Hepatocellular Carcinoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study is designed to evaluate the possible benefits and side effects of the use of proton therapy for patients with hepatocellular carcinoma.
Condition or disease
Liver CancerHepatocellular Carcinoma
Radiation: Proton radiation therapy
Phase 1Phase 2
Hepatocellular carcinoma (HCC) is a type of primary cancer of the liver that is being diagnosed in the U.S. population with increasing frequency. While surgery is the first line of treatment, many patients are not eligible for surgical removal. Current non-surgical treatments for HCC are not fully effective and can have substantial side-effects. This study utilizes a type of radiation treatment called proton beam that can deliver high doses of radiotherapy to tumors within the liver while minimizing damage to surrounding healthy tissues. The treatment is non-invasive and is given on an out-patient basis over a three week coarse. The study will evaluate the effectiveness and side-effects of this therapy by tracking patient's outcomes following treatment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosis of hepatocellular carcinoma
Adult patients aged 18 years old and above
Ability to give informed consent for study
Compensated liver disease
Pediatric patients (aged less than 18 years old)
Decompensated or advanced liver disease
Poorly controlled ascites
Variceal hemorrhage within the previous 30 days
Recurrent hepatic encephalopathy
Cirrhosis with CTP* score >10
Active alcohol or drug abuse
Anticipated survival of less than 30 days
Advanced co-morbid medical illnesses
Karnofsky Performance Score <60
- Any tumor that can not be safely and effectively irradiated due to inability to deliver target treatment dose to required treatment volume or due to prohibitively high risk of anticipated toxicities to normal liver or nearby bowel, stomach, kidney or spinal cord.